Gs12-10 endonuclease variant and gene editing system mediated by same

By mutation of Gs12-10 endonuclease and crRNA scaffold, the CRISPR/Gs12-10MAX system was developed, which solved the problem of low cleavage efficiency in the existing technology, achieved efficient gene editing, and expanded its in gene therapy and agriculture Breeding application.

CN119082085APending Publication Date: 2024-12-06HUBEI HONGSHAN LABORATORY +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411345829.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing CRISPR/Gs12-10 gene editing technology has a large range of editing but low cutting efficiency, which limits its application potential in gene therapy and agricultural biological breeding.

Method used

By mutation of the scaffold loop region of Gs12-10 endonuclease and crRNA scaffold, the best combination was screened, and the CRISPR/Gs12-10MAX system was developed, which improved the targeted site-point cleavage efficiency of gene editing.

Benefits of technology

It significantly improves gene editing activity and specificity, provides efficient gene editing tools, and expands its application prospects in gene therapy and agricultural biological breeding.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005060937310000031
    Figure BDA0005060937310000031
  • Figure BDA0005060937310000041
    Figure BDA0005060937310000041
  • Figure BDA0005060937310000051
    Figure BDA0005060937310000051
Patent Text Reader

Abstract

The invention discloses a Gs12-10 endonuclease variant and a gene editing system mediated by the Gs12-10 endonuclease variant. Specifically, the 156th amino acid of Gs12-10 endonuclease is mutated from Glu to Arg, the variant is called Gs12-10MAX, the length of crRNA is optimized, and a scaffold loop region sequence in crRNA scaffold is modified, so that the CRISPR / Gs12-10 MAX system mediated genome editing efficiency is remarkably improved, and the CRISPR / Gs12-10 MAX mutant has a wide application prospect in the field of genome site-specific modification.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of genome editing, and specifically relates to a Gs12-10 endonuclease variant and a gene editing system mediated by the variant. Background Art

[0002] Genetic variation is the basis for breeding improvement, and the purpose of animal breeding is to create and utilize these genetic variations. In the long history of animal genetic breeding, four main strategies have been adopted: hybrid breeding, genomic selection breeding, transgenic breeding and genome editing breeding. Traditional animal breeding, namely hybrid breeding, has played an important role in improving animal genetic improvement through sexual recombination through purposeful hybridization combined with selection of ideal phenotypes. However, since hybrid breeding can only introduce traits already present in the parental genome, the low genetic diversity in excellent germplasm limits the potential of this technology. Genomic selection is a method of estimating breeding values ​​using molecular marker effects, which does not rely on pedigrees to estimate genetic connections and can solve the above problems. The application of genomic selection technology to optimize the allocation of breeding resources on the basis of the existing core group can make my country's pig genetic evaluation more accurate, promote the continuous, stable and effective joint breeding of my country's breeding pigs, and thus improve the overall efficiency of my country's breeding pigs. However, there is also the disadvantage that natural variation is difficult to aggregate. Transgenic breeding is a key breakthrough in animal breeding, which introduces genes or traits from other organisms into the animal genome to increase growth rate, resist disease infection and improve meat quality. However, so far, only a few traits can be achieved through transgenics because this technology randomly integrates foreign DNA into the animal genome, and these genetically modified organisms (GMOs) are strictly regulated by the government.

[0003] The development of genome editing technology makes it possible to introduce precise and predictable genome modifications in animals to obtain desired traits. These technologies are defining the next generation of animal breeding, namely precision breeding technology. In addition, this technology can also be used for human gene therapy. In particular, CRISPR-Cas technology has become one of the most advanced tools for transforming animal genomes. This technology has been rapidly expanded and applied to human disease treatment, epidemic prevention and control, and animal disease-resistant breeding research. The inventors used a strategy combining bioinformatics and experiments to develop a CRISPR / Gs12-10 gene editing technology (CN116286737A) with a small PAM restriction range. However, the evaluation found that although the target editing range of this technology is large, it has the disadvantage of low cutting efficiency. Therefore, the present invention further improves Gs12-10 and crRNA variants, screens out the best combination, and then greatly improves the efficiency of targeted site cutting of this gene editing technology, providing new tools for gene therapy and agricultural biological breeding. Summary of the invention

[0004] The present invention simultaneously mutates the amino acid sequence of Gs12-10 endonuclease and the scaffold loop region of crRNA scaffold, screens the best combination, and develops an efficient gene editing technology mediated by CRISPR / Gs12-10MAX system.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions:

[0006] A nuclease variant in a CRISPR / Gs12-10 system, comprising the following proteins:

[0007] I. Gs12-10MAX protein having an amino acid sequence as shown in SEQ ID NO.1, wherein the amino acid at position 156 is mutated from Glu to Arg relative to the wild-type Gs12-10 endonuclease;

[0008] II. A protein having one or more amino acids substituted, deleted or added compared to the amino acid sequence shown in SEQ ID NO.1, and substantially retaining the biological function derived from the sequence.

[0009] Fusion protein, including the above protein and other modified parts.

[0010] A polynucleotide encoding the above-mentioned endonuclease variant or the above-mentioned fusion protein. A vector or host cell comprising the polynucleotide.

[0011] The application of the above-mentioned nuclease variants in gene editing includes modifying genes in prokaryotic genomes, eukaryotic genomes or in vitro genes, knocking out genes, changing the expression of gene products, repairing mutations or inserting polynucleotides.

[0012] A CRISPR / Gs12-10MAX gene editing system, comprising the above-mentioned endonuclease variant, or the above-mentioned fusion protein, or the above-mentioned polynucleotide, or the above-mentioned vector, or the above-mentioned host cell; and also comprising crRNA, the scaffold sequence of the crRNA is shown in SEQ ID NO.2, and the length of the targeted gene editing site in the crRNA is 23nt.

[0013] The technical solution of the present invention has the following main beneficial effects:

[0014] 1. The present invention provides for the first time Gs12-10MAX, crRNA variants and their optimal combination, which improves gene editing activity compared to the unmodified CRISPR / Gs12-10 system.

[0015] 2. The present invention develops a highly efficient gene editing technology mediated by the CRISPR / Gs12-10MAX system, which has broad application prospects in the field of genome site-specific modification. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 .Evaluation of the effect of crRNA length on gene editing activity mediated by the CRISPR / Gs12-10 system; A. Gene editing activity evaluation model diagram by co-transfection of Gs12-10 and crRNA expression plasmid; B. Comparison of genome editing activity of crRNAs of different lengths. The cells were human HEK 293T cells, ****P<0.0001.

[0017] Figure 2 . Identification of crRNA variants with the highest genome editing activity using the green fluorescent protein (ZsGreen) repair reporter system; A. Schematic diagram of the working principle of the ZsGreen repair reporter system; B. Comparison of the genome-targeted editing activities of different crRNA scaffold variants. ***P<0.001, ****P<0.0001.

[0018] Figure 3 .Identification of Gs12-10 endonuclease variants with the highest activity using the ZsGreen repair reporter system; A. Schematic diagram of different variants of Gs12-10 endonuclease; B. Detection of six Gs12-10 variants (Gs12-10D547R, Gs12-10E156R, Gs12-10D547R / K553V, Gs12-10E156R / C. Detection of genome editing activity of three Gs12-10 variants (Gs12-10E156R, Gs12-10D547R / K553V and Gs12-10E156R / D547R) in porcine PK-15 and mouse L929 cells. ****P<0.0001.

[0019] Figure 4 .The specificity of CRISPR / Gs12-10MAX variants was evaluated using the ZsGreen repair reporter system; A. The targeted editing specificity of the Gs12-10MAX variants against two base mismatch sites was detected using the ZsGreen repair reporter system; B. The cleavage activity of the Gs12-10MAX variants against potential off-target sites of the endogenous target site predicted by the software was detected using the T7E1 (T7 Endonuclease I) enzyme digestion assay. PAM, protospacer adjacent motif. DETAILED DESCRIPTION

[0020] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0021] Example 1. Determining the optimal crRNA length to enhance CRISPR / Gs12-10 gene editing activity

[0022] This embodiment first compares and determines the optimal length of crRNA that can enhance the CRISPR / Gs12-10 gene editing activity. By liposome transfection means, the Gs12-10 endonuclease (CN116286737A) and different length crRNA expression vectors identified by the inventor in the early stage are co-transfected into HEK 293T cells, and the crRNA paired with the target nucleic acid is used to guide the Gs12-10 endonuclease to recognize and bind to the target nucleic acid, thereby stimulating its genome cutting activity. Finally, cells are collected and genomic DNA is extracted, and the editing activity of different target lengths at different target positions is analyzed by T7E1 enzyme cutting experiments.

[0023] The target genes selected in this embodiment are human DNMT1, FANCF and EMX1 genes, the PAM recognized by crRNA is TTTV, the sequences of crRNAs of different lengths are shown in Table 1, the non-underlined region is the wild-type scaffold (AAUUUCUACUAUUGUAGAUU), and the underlined region is the base complementary pairing region. They are respectively constructed into specific crRNA eukaryotic expression vectors.

[0024] Table 1. Names of crRNA and corresponding nucleotide sequences

[0025]

[0026]

[0027]

[0028] HEK 293T cells were plated when the confluence reached 70-80%, and the number of cells seeded in a 12-well plate was 8 × 10 4Cells / well. Transfection was performed 6-8 hours after plating. 1 μg of Gs12-10 eukaryotic expression vector plenti-Gs12-10-NLS-puro with NLS nuclear localization signal, 500 ng of crRNA expression vector plenti-U6-crRNA-zsGreen targeting different genes and different lengths, and 10 μL Jetprime regent were added to 200 μL Jetprime Buffer in sequence, pipetting and mixing, and incubating at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After culturing at 37°C for 72 hours, the culture medium was discarded, the cells were resuspended with 100 μL PBS, and the cell genome was extracted. The target site of the transfected positive cells was PCR amplified to edit the sequence near it. The PCR product was recovered and the editing activity was analyzed by T7E1 enzyme digestion and gel running experiment ( Figure 1 A).

[0029] The length range of the region matching the target gene in the crRNA selected for evaluation was 20-25 base pairs (nt). Figure 1 As shown in Figure 2, it was found that when the length of the region matching the target gene in the crRNA was 22nt and 23nt, the CRISPR / Gs12-10 gene editing activity was relatively the highest. In addition, by comparing the genome editing efficiency targeting DNMT1 and FANCF, it was found that the crRNA with a length of 23nt matching the target gene was better than the crRNA with a length of 22nt matching the target gene. Therefore, it was determined through comparative experiments that the crRNA that can specifically mediate the best CRISRP / Gs12-10 gene editing activity has a length of 23nt matching the target gene ( Figure 1 B).

[0030] Example 2. Identification of optimal crRNA variants that can improve CRISPR / Gs12-10 gene editing activity

[0031] In order to further enhance the gene editing activity of CRISPR / Gs12-10, this embodiment performs base deletion and substitution on the scaffold loop region of the crRNA scaffold, thereby screening out the best crRNA variant that can enhance the gene editing activity of CRISPR / Gs12-10. In order to efficiently evaluate the targeted cleavage activity of different crRNA variants, this embodiment establishes a gene editing activity evaluation strategy based on the ZsGreen repair reporter system, the working principle of which is that different crRNA variants guide the Gs12-10 nuclease to cause editing of the target genome, thereby causing the insertion or deletion of small fragments, so that the inactivated ZsGreen is restored to expression in the cell, and then the expression level of the fluorescent protein is identified by flow cytometry, thereby quantifying and conveniently screening the best crRNA variant that enhances the gene editing activity of CRISPR / Gs12-10 ( Figure 2 A).

[0032] The crRNA variant sequences used for the ZsGreen repair reporter system in this embodiment are shown in Table 2. The non-underlined regions are different scaffold variants, and the underlined regions are paired regions targeting different fragments. Among them, crRNA1 is a non-target DNA strand nucleotide sequence targeting Chain O (NCBI accession number: 8FD3_O), and crRNA2 targets the ASFV p72 gene (NCBI accession number: MZ812157.1). These crRNA variants are constructed into the crRNA eukaryotic expression vector containing the ZsGreen repair reporter system.

[0033] Table 2. Names of different crRNA variants and their corresponding nucleotide sequences

[0034]

[0035] HEK 293T cells were plated when the confluence reached 70-80%, and the number of cells seeded in a 12-well plate was 8 × 10 4Cells / well. After plating for 6-8 hours, transfection was performed. 1 μg of Gs12-10 eukaryotic expression vector plenti-Gs12-10-NLS-puro with NLS nuclear localization signal, 500 ng of ZsGreen repair reporter system eukaryotic expression vector plenti-U6-crRNA-N7-zsGreen containing crRNA variants and 10 μL Jetprime regent were added to 200 μL Jetprime Buffer in sequence, pipetted to mix, and incubated at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After culturing at 37°C for 72 hours, the culture medium was discarded and the cells were resuspended in 100 μL PBS. The percentage of green fluorescent protein in the cells was calculated by flow cytometry, and the gene editing activity of the crRNA variants could be evaluated ( Figure 2 A).

[0036] The results are as follows Figure 2 As shown in B, by changing the crRNA scaffold loop region, it was found that compared with the wild type "crRNA1-UAUU" (Table 2), when two bases "AU" were added to the loop region of the crRNA scaffold, that is, "crRNA1-UAUUAU" (Table 2), the Gs12-10 endonuclease guided by this crRNA variant had the highest gene editing activity. Thus, through comparative experiments, it was found that the crRNA variant with the crRNA scaffold loop region of "UAUUAU" can significantly improve the genome editing activity of the CRISPR / Gs12-10 system.

[0037] Example 3. Screening and identification of highly active Gs12-10 endonuclease variants

[0038] In this embodiment, Gs12-10 endonuclease was modified by amino acid mutation, in order to optimize the combination with the above-mentioned optimal crRNA length and scaffold modified crRNA variants, thereby improving the genome editing activity of the CRISPR / Gs12-10 system. In order to accurately evaluate the genome editing activity of the CRISPR / Gs12-10 system, this embodiment continues to use the above-mentioned ZsGreen repair reporter system for activity evaluation. Its working principle is that when the crRNA variant guides the Gs12-10 endonuclease variant to recognize the target genome sequence, it will activate its genome editing and then produce small fragments of insertion or deletion at the target site, resulting in the repeated restoration of inactivated green fluorescent protein in the cell. Expression, and finally, the expression level of the fluorescent protein is analyzed by flow cytometry, and the genome editing activity of the modified CRISPR / Gs12-10 system can be accurately detected. At the same time, the activity of the modified CRISPR / Gs12-10 system in different mammalian cells was further compared, and gene editing activity tests were performed on human HEK293T cells, pig PK-15 and mouse L929 cells.

[0039] The optimal crRNA variant used in this example is crRNA1-UAUUAU (Table 2), and a specific crRNA eukaryotic expression vector plenti-U6-crRNA-N7-zsGreen containing a ZsGreen repair reporter gene is constructed, wherein crRNA1 is a nucleotide sequence targeting the Non-target DNA strand in Chain O. Figure 3 As shown in Figure A, there are 6 Gs12-10 endonuclease variants, including Gs12-10E156R (amino acid mutated from Glu at position 156 to Arg), Gs12-10D547R (amino acid mutated from Asp at position 547 to Arg), Gs12-10D547R / K553V (amino acid mutated from Asp at position 547 to Arg, and amino acid mutated from Lys at position 553 to Val), Gs12-10E156R / D547R (amino acid mutated from Asp at position 156 to Arg, and amino acid mutated from Lys at position 553 to Val). The 547th amino acid mutates to Arg by Glu, and the 547th amino acid mutates to Arg by Asp), Gs12-10D547R / K553R (the 547th amino acid mutates to Arg by Asp, and the 553rd amino acid mutates to Arg by Lys) and Gs12-10E156R / D547R / K553V (the 156th amino acid mutates to Arg by Glu, the 547th amino acid mutates to Arg by Asp, and the 553rd amino acid mutates to Val by Lys). Table 3 lists the crRNA sequences targeting CD163 gene in pig PK-15 cells, and the specific crRNA sequences targeting Tyr gene in mouse L929 cells.

[0040] Table 3. Specific crRNA sequences in porcine PK-15 and mouse L929 cells

[0041]

[0042] HEK 293T cells were plated when the confluence reached 70-80%, and the number of cells seeded in a 12-well plate was 8 × 10 4 Cells / well. After 6-8 hours of plating, transfection was performed. 1 μg of eukaryotic expression vector containing Gs12-10 variant, 500 ng of expression vector fused with ZsGreen repair reporter gene and crRNA, and 10 μL of Jetprime regent were added to 200 μL Jetprime Buffer in sequence, pipetting and mixing, and incubated at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After culturing at 37°C for 72 hours, the culture medium was discarded and the cells were resuspended in 100 μL PBS. The gene editing activity of the Gs12-10 variant was detected by flow cytometry analysis of the percentage of green fluorescent protein.

[0043] At the same time, HEK 293T cells with good growth status for about 3 generations were taken for lentiviral packaging. In a 10 cm culture dish, the total amount of plasmids for lentiviral packaging was 24 μg. The corresponding volumes of plasmids were added to 500 μL Jetprime Buffer in sequence, where pmd2.g:pspax2:plasmids with Gs12-10 variants (plenti-Gs12-10E156R-puro or plenti-Gs12-D547R / K553V-puro or plenti-E156R / D547R-puro) or crRNA expression vector plenti-U6-crRNA-zsGreen = 1:2:3. After gently pipetting and mixing, 40 μL Jetprime was added. regent, let stand at room temperature for 10 minutes and then added to the culture dish; the Gs12-10 variant and crRNA expression lentiviral supernatant were taken 60 hours after transfection and co-infected into porcine PK-15 or mouse L929 cells, respectively. Finally, the cells were collected and genomic DNA was extracted, and the targeted cleavage activity was analyzed by T7E1 enzyme cleavage experiment.

[0044] The results are as follows Figure 3As shown in B, it was found that compared with the wild-type CRISPR / Gs12-10, the six modified Gs12-10 variants can significantly improve their genome editing activity. Relatively speaking, the Gs12-10E156R variant has the greatest gene editing activity compared to D547R / K553V and E156R / D547R. Further, the gene editing activity of these three Gs12-10 variants was tested in different mammalian cells. The results showed that the Gs12-10E156R variant had the highest gene editing activity in both porcine PK-15 and mouse L929 cells ( Figure 3 C). Therefore, through comparative experiments, it was identified that the Gs12-10E156R variant had the highest gene editing activity, and was therefore named the Gs12-10MAX variant.

[0045] Example 4. Detection of the specificity of CRISPR / Gs12-10MAX gene editing technology

[0046] This example further evaluates the specificity of the CRISPR / Gs12-10MAX gene editing technology. The ZsGreen repair reporter system will also be used for experimental detection. Its general working principle is: when the modified crRNA guides the Gs12-10MAX variant to identify the targeted gene site with two base mismatches, it can identify its gene editing specificity. If the genome editing does not produce the insertion or deletion of small fragments, and the inactivated green fluorescent protein cannot be restored to expression in the cell, it can be shown that the gene editing technology has a high specificity. At the same time, in HEK 293T cells targeting endogenous genes, the CRISPR-offinder software is first used to predict the potential off-target sites of crRNA, and the T7E1 enzyme cutting experiment is used to further detect the cutting activity of CRISPR / Gs12-10MAX on non-targets, so as to systematically evaluate the specificity of CRISPR / Gs12-10MAX gene editing technology.

[0047] The crRNA sequences containing two mismatched targeted gene sites in this embodiment are shown in Table 4, the underlined region is the target gene matching region, the bold bases are the sites mismatched with the target, and are respectively constructed into a eukaryotic expression vector containing a specific crRNA of the ZsGreen repair reporter system. At the same time, the potential off-target sites of crRNA are predicted by CRISPR-offinder software, and the predicted off-target sites and PCR amplification primers are shown in Table 4.

[0048] Table 4. PCR primer pairs for detecting crRNA on-target and predicting off-target activity

[0049]

[0050]

[0051] HEK 293T cells were plated when the confluence reached 70-80%, and the number of cells seeded in a 12-well plate was 8 × 10 4 Cells / well. After 6-8 hours of plating, transfection was performed. 1 μg of Gs12-10MAX eukaryotic expression vector, 500 ng of crRNA expression vector containing ZsGreen repair reporter gene, or wild-type crRNA expression vector and 10 μL of Jetprime regent were added to 200 μL of Jetprime Buffer in sequence, mixed by pipetting, and incubated at room temperature for 10 minutes. The incubated mixture was added to the culture medium with cells for transfection. After 72 hours of culture at 37°C, the culture medium was discarded and the cells were resuspended in 100 μL of PBS. The percentage of green fluorescent protein was detected by flow cytometry to detect the genome editing specificity of CRISPR / Gs12-10MAX. At the same time, the cells were finally collected and genomic DNA was extracted, and PCR amplification was performed on the predicted off-target sites. The products were recovered and further tested for their specificity by T7E1 restriction enzyme digestion experiment.

[0052] The results are as follows Figure 4 As shown in A, it was found that when there were two base mismatches between the target site and crRNA, Gs12-10MAX could not restore ZsGreen green fluorescence expression except for the last two base mismatches of the target. This experiment showed that CRISPR / Gs12-10MAX technology has relatively high genome editing specificity. Further, in HEK 293T cells, the cleavage activity was detected for the potential off-target sites predicted by its endogenous target site, and it was found that the predicted off-target sites did not undergo cleavage ( Figure 4 B). It can be seen that the enhanced CRISPR / Gs12-10MAX gene editing system developed by the present invention has high specificity.

[0053] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with the field can make some changes or modify the technical contents suggested above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the solution of the present invention.

Claims

1. A nuclease variant in the CRISPR / Gs12-10 system, characterized in that Includes the following proteins: I. Gs12-10MAX protein having an amino acid sequence as shown in SEQ ID NO.1, wherein the amino acid at position 156 is mutated from Glu to Arg relative to the wild-type Gs12-10 endonuclease; II. A protein having one or more amino acids substituted, deleted or added compared to the amino acid sequence shown in SEQ ID NO.1, and substantially retaining the biological function derived from the sequence.

2. A fusion protein, characterized in that Comprising the protein according to claim 1 and other modified parts.

3. A polynucleotide, characterized in that The polynucleotide is a polynucleotide encoding the endonuclease variant according to claim 1, or a polynucleotide encoding the fusion protein according to claim 2.

4. A carrier, characterized in that The vector comprises the polynucleotide of claim 3.

5. A host cell, characterized in that The host cell comprises the polynucleotide of claim 3 or the vector of claim 4.

6. Use of the endonuclease variant according to claim 1, or the fusion protein according to claim 2, or the polynucleotide according to claim 3, or the vector according to claim 4, or the host cell according to claim 5 in gene editing.

7. A CRISPR / Gs12-10MAX gene editing system, characterized in that: It comprises the endonuclease variant of claim 1, or the fusion protein of claim 2, or the polynucleotide of claim 3, or the vector of claim 4, or the host cell of claim 5.

8. The gene editing system according to claim 7, characterized in that: It also includes crRNA, the scaffold sequence of the crRNA is shown in SEQ ID NO.2, and the length of the targeted gene editing site in the crRNA is 23 nt.

Citation Information

Patent Citations

  • PAM-limitation-free endonuclease and gene editing system mediated by same

    CN116286737A